Huatai Zijin Investment
VC Fund
Nanjing, China
Huatai Zijin Investment is an invetsment Firm.
- Total investments:
- 62
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries Huatai Zijin Investment invests in
Stages Huatai Zijin Investment invests in
Countries Huatai Zijin Investment invests in
Round sizes
Contacts
3 more contacts available
Round size
- Series A
- $1.4M–$290M
- Series B
- $15M–$76M
Investment Focus
Industry
- Health Care 14 (23%)
- Biotechnology 10 (16%)
- Medical 9 (15%)
- Manufacturing 9 (15%)
- Pharmaceutical 7 (11%)
Stage
- Series B 12 (19%)
- Series A 6 (10%)
- Funding Round 6 (10%)
- Seed 5 (8%)
- Series C 5 (8%)
Country
- China 39 (63%)
- United States 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Chen Miao
partner
|
partner | Total investments: 3 | Find email | |
|
Wang Qi
investment director
|
investment director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Weiguang Energy Technology
|
Weiguang Energy Technology focuses on the research, manufacturing, and commercial application of advanced power electronics equipment, specifically solid-state transformers and energy routing technologies. The company operates a core business model centered on supplying tailored hardware and digital software platforms to optimize energytransformation. Its primary value proposition is to enhance efficiency, system safety, and battery life management within computing infrastructure, electrical transportation grids, and large-scale energy storage installations. | Series B / Aug 02, 2026 | |
Genta Kyushu Bio
|
Genta Kyushu Bio is a cutting edge biotechnology company specializing in the development of precision neuro circuit therapies for central nervous system and ophthalmic diseases. The firm leverages its high throughput screening and drug development platforms to advance innovative treatments utilizing chemogenetics, optogenetics, and gene therapies. | $14.8M / Series A / Jul 30, 2026 | |
Kai Medtech
|
Kai Medtech focuses on the research, development, production and sales of neurointerventional implantable medical devices. | $73.9M / Series D / Jul 28, 2026 | |
Lyen Marine
|
LYEN is committed to designing and producing reliable, high-performance propeller systems, including FPP, CPP, and Azimuth thrusters. | $14.7M / Series B / May 22, 2026 | |
|
Vita Dynamics
|
Vita Dynamics involves learning through real-world interactions by developing robots that can physically engage with their environment, they can adapt more naturally and efficiently. | $73.6M / Seed / May 11, 2026 | |
Suzhou Shincell New Material
|
Suzhou Shensai New Materials manufacturers environmentally friendly clean foaming materials and other lightweight materials. | $28.9M / Series B / Mar 23, 2026 | |
Spirit AI
|
Spirit AI develops 'Universal Brains' for robotics, specializing in general-purpose embodied models that bridge the gap between simulation and real-world deployment. These models provide robots with robust generalization and precise physical interaction capabilities across diverse environments. Technical efficacy is validated by theSpirit Series (notably Spirit v1.5), which currently leads the RoboChallenge global benchmarks. Through rigorous R&D, Spirit AI aims to integrate versatile robotic companions into the modern workforce, advancing the era of embodied AI. | $290M / Series A / Feb 24, 2026 | |
Haipu Functional Materials
|
Haipu is dedicated to assisting national businesses in realizing the recycling of wastewater and waste gas resources and in meeting environmental protection criteria. It is a supplier of materials for adsorption and separation as well as eco-friendly approaches to environmental protection. Their business specializes in the research and developmentof performance adsorbents, catalysts, and process applications, empowering businesses in the chemical, pharmaceutical, environmental, and new energy sectors. | $14.5M / Series B / Feb 24, 2026 | |
Huaxing Laser
|
Huaxing Laser specializes in the development and manufacturing of semiconductor laser epitaxial wafers and photodetector epitaxial wafers for the sensing and communication areas. | $14.3M / Series D / Dec 30, 2025 | |
Qingwei Intelligent Technology
|
Qingwei Intelligent Technology is a Chinese artificial intelligence (AI) chip maker | $282.9M / Series C / Dec 02, 2025 | |
| See all 62 investments → | |||
Co-Investors
Highlight Capital
5 deals together
Shunwei Capital
4 deals together
Alibaba Group
3 deals together
Fosun RZ Capital
3 deals together
Guoqian Venture Capital
3 deals together
Prosperity7 Ventures
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Huatai Zijin Investment invest in?
Huatai Zijin Investment invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 62 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Huatai Zijin Investment's check size?
Huatai Zijin Investment typically joins rounds of $1.4M–$290M at Series A and $15M–$76M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Huatai Zijin Investment participates in.
How do I contact Huatai Zijin Investment?
Public channels for Huatai Zijin Investment include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Huatai Zijin Investment?
The team at Huatai Zijin Investment includes Chen Miao (partner) and Wang Qi (investment director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
